



STAR COMBO PHARMA LTD
ABN 38 6157 283 75
171 -177 Woodpark Rd
Smithfield NSW 2164
P: +61 2 9756 6555
sales@starcombo.com.au

28 May 2024

ASX Announcement

Star Combo Pharma Product Update

Highlights

- **Facility 2 production upgrade completed at 171-177 Woodpark Rd**
- **Star Combo receives TGA approval for Gummy manufacturing**
- **Market presents revenue opportunities**

Star Combo Pharma Limited (ASX: S66) (Star Combo) is pleased to confirm that the Therapeutic Goods Administration (TGA) has recently issued a licence to Star Combo for the full product manufacture (excluding testing) of pastille products for the Gummy market.

Following this confirmation Star Combo has further investigated the Gummy market and is looking to secure new customers and revenues to further add to its growing current OEM Revenues.

The group OEM and Own Brand unaudited revenues to the end of April 2024 are 19% ahead of the equivalent FY 23 revenues.

Star Combo believes that a successful entry to Gummy manufacturing will enhance its domestic and international revenue growth prospects.

Set out in the Attachment: Pastille Production Line Project Introduction is a brief summary of historical Star Combo revenues and some of the relevant attributes of the Gummies market

-ENDS-

This ASX announcement has been approved by the CEO of Star Combo Pharma Limited.

Investor and Media relations contact

investors@starcombo.com.au

About Star Combo Pharma

Star Combo Pharma Ltd (ASX: S66) is a Sydney based contract manufacturer of vitamins, health and beauty products with a portfolio of own brands and distribution capabilities. Our products are made from natural ingredients with scientific R&D and adheres to the highest manufacturing practices governed by the Therapeutic Goods Administration. Star Combo has offices in China and currently supplies the Australian pharmacy network through 450 Terry White Chemmart stores as well as wholesale customers in Australia and China. Directed by pharmacist and experts in health supplement manufacturing, Star Combo's vision is to be the leading manufacturer of premium vitamins and dietary supplements in Australia. Since its establishment in 2004, Star Combo has demonstrated strong product and business development and continues to expand our current operations to serve our loyal business partners, customers and employees.



PASTILLE(Gummy) PRODUCTION LINE

PROJECT INTRODUCTION



STARCOMBO

STAR COMBO PHARMA LIMITED

Listed on the Australian Stock Exchange

- Facility 2 pastille production line upgrade completed
- Expansion of pastille (gummy) product lines provides revenue growth opportunities with daily maximum capacity at 3 million gummies
- OEM and Own Brand Revenue is growing
 - Audited Results
 - FY22 Revenue = \$16.2m FY23 Revenue = \$20.8m
 - Year on Year growth = 28%
 - Unaudited Results
 - April 23 YTD Revenue = \$15.5m April 24 YTD Revenue \$18.4m
 - Year on Year growth = 19%
- Additional production capacity and capabilities are in place to supply the market.

GUMMY PRODUCT OUTLOOK

STARCOMBO

The growth rate of gummies varies due to factors such as market demand, consumer preferences, and competition.

01

In recent years, due to the increasing interest of consumers in functional and fortified candy products, the global gummy market has shown stable growth.

02

Soft candies are highly popular among children and adults, helping to expand the market.

03

The innovation in taste, shape, and formula caters to different tastes and dietary preferences, driving market growth.

04

The trend of adding vitamins, minerals, and other health promoting ingredients to gummies has further expanded the market.

05

Although the specific growth rate may fluctuate, the overall trajectory of the gummy market indicates the existence of sustained growth and development opportunities.

06

GUMMY PRODUCT OUTLOOK continued

STARCOMBO

Global Gummy Supplements Market Overview

Gummy Supplements Market Size was valued at USD 5.5 billion in 2022. The gummy supplements industry is projected to grow from USD 6.004 Billion in 2024 to USD 10.2 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.17% during the forecast period (2024 - 2030).



GUMMY PRODUCT OUTLOOK continued

STARCOMBO

01

Gummy supplements often provide similar benefits to their traditional multivitamins or other dietary supplement equivalents.

02

Gummy supplements have one main advantage over other supplements: they taste like candy and are easy to take, making them appealing to many people and children who might not enjoy taking pills.

03

Gums and jellies come in a vast array of shapes, sizes, and textures.

04

Flavors range from cherry, pink grapefruit, and watermelon to strawberry, orange, and blue raspberry.

05

Ingredients may include gelatin alone or in combination with starches, pectin, or agar.

06

Gelling agents bind a concentrated sugar solution, ensuring shelf stability.

07

Gums and jellies offer convenient, on-the-go enjoyment with a long shelf life.

08

Manufacturers continuously innovate with new flavor combinations and textures.



GUMMY PRODUCT OUTLOOK continued

STARCOMBO

01

Star Combo is a TGA authorised gummy manufacturer and supplier in Australia, renowned for their dedication to quality and innovation. Our gummy supplements are nutritional supplements in the form of gummies, typically composed of vitamins.

02

Our most advanced gummy machines are proudly manufactured in Australia, capable of producing high-quality, low sugar gummies in various forms and flavors. They are often used as more delicious alternatives to other supplement formulas.

03

Our nutritional gummies are rich in essential vitamins, minerals, Omega-3, probiotics, and other functional ingredients. They are made from genuine fruit juice and natural spices, providing a delicious and convenient health and well-being product.

04

At Star Combo Pharma, we prioritise excellence in all aspects of the production process, ensuring that each type of gummy meets the highest standards of taste, quality, and nutritional value. We believe that we will provide both healthy and enjoyable gummies to help customers live the best and healthiest life.



GUMMY PRODUCT OUTLOOK continued

STARCOMBO

"The benefits of gelatin in chewing gum and jelly"



01

Gelatin gives chewing gum and jelly a clear and transparent appearance, enhancing their visual appeal.

03

Chewing gum and jelly made from gelatin have a unique flavor release, bringing a pleasant "melt on the go" experience.

05

The gelatin content in chewing gum and jelly can be adjusted between 3% and 12%, depending on the desired texture, gelatin color, and combination with other hydrophilic colloids.

02

Gelatin provides a pleasant elastic texture for chewing gum and jelly, bringing a satisfying chewing sensation.

04

Gelatin gum does not stick to teeth, making it more enjoyable to consume and without any residue that may cause inconvenience.

06

Chewing gum and jelly are usually stored in starch molds, however, as the gelatin content increases (up to 12%), starch free molding technology can be used to achieve efficient production.

DISCLAIMER

The information in this presentation is not a prospectus or other form of disclosure document prepared in accordance with the requirements of the Corporations Act 2001 (Cth) (Corporations Act) and will not be lodged with the Australian Securities and Investments Commission (ASIC). This presentation provides information in summary form and general information regarding Star Combo Pharma Ltd ACN 615 728 375 (Star Combo or the Company) and the proposed placement to sophisticated and professional investors.

This presentation contains information, ideas and analysis which are proprietary to Star Combo. By agreeing to receive this information you also agree to respect the confidential nature of this entire presentation. Specifically you agree not to reproduce in any manner any part of the information contained herein without our prior written consent. This presentation is not complete, is intended only as an outline and has been prepared by and issued by Star Combo to assist in informing interested parties about the Company and should not be considered as an offer or invitation to subscribe for or purchase any securities in the Company or as an inducement to make an offer or invitation with respect to those securities. No agreement to subscribe for securities in the Company will be entered into on the basis of this presentation.

This presentation is current as at the date on the cover page. The information in this presentation, therefore, remains subject to change. The Company is under no obligation to update the presentation and the information in this presentation remains subject to change by the Company in its absolute discretion and without notice.

This presentation may contain forward looking statements. Whilst the Company has no reason to believe that any such statements are either false, misleading or incorrect, it cannot and does not warrant or guarantee that through either the passage of time or actions beyond the control of the company they will not become so. Actual results, performance or achievements could be significantly different from those expressed in, or implied by, these forward-looking statements. Nothing contained in this presentation constitutes investment, legal, tax or other advice. This overview of investment does not purport to be all inclusive or to contain all information which its recipients may require in order to make an informed assessment of the Company's prospects.

The Company's statutory results are prepared in accordance with International Financial Reporting Standards ("IFRS"). This presentation also includes certain non-IFRS measures in presenting the Company's results. Any additional financial information in this presentation which is not included in the Company's 30 June 2018 Financial Statements was not subject to independent audit or review. Investors should be aware that certain financial data included in this presentation is "non-IFRS financial information" under ASIC Regulatory Guide 230: "Disclosing non-IFRS financial information" published by ASIC and may also be "non-GAAP financial information" within the meaning given under Regulation G of the U.S. Securities Exchange Act of 1934, as amended.

Non-IFRS financial information does not have a standardised meaning prescribed by Australian Accounting Standards ("AAS"). Accordingly, the non-IFRS financial information in this presentation: (i) may not be comparable to similarly titled measures presented by other entities; (ii) should not be construed as an alternative to other financial measures determined in accordance with AAS; and (iii) is not a measure of performance, liquidity or value under the IFRS. Investors are cautioned, therefore, not to place undue reliance on any non-IFRS financial information included in this presentation.

To the maximum extent permitted by law, the Company and its advisers make no representation and give no assurance, guarantee or warranty, express or implied, as to, and take no responsibility and assume no liability for, the authenticity, validity, accuracy, suitability or completeness of, or any errors in or omissions, from any information, statement or opinion contained in this presentation. All values are expressed in Australian currency unless otherwise stated.

This presentation is not for release to US wire services or distribution in the United States or any country where it may be unlawful. See "International Offer Restrictions".

End

Investor relations

investors@starcombo.com.au